Is PN-943 legal in the US?
No. It is not approved, and its maker is looking for a partner to take it on.
PN-943 is an investigational oral peptide that is not approved by the FDA for any use. After the phase 2 IDEAL trial in ulcerative colitis reported in 2022, its sponsor, Protagonist Therapeutics, said it would put no further internal resources into the program and would look for a licensing partner. No phase 3 trial has been registered.
No. It is an investigational compound that has not gone beyond phase 2. No phase 3 trial has been registered. Protagonist said in November 2022 that it would put no further internal resources into the program and would look for a licensing partner. 23
More on PN-943
Citations
- Sandborn 2021, Gastroenterology: PTG-100, an oral alpha4beta7 antagonist peptide, preclinical development and phase 1 and 2a studies in ulcerative colitis doi.org
- HCPLive 2022: phase 2 IDEAL trial results for PN-943 in ulcerative colitis hcplive.com
- BioSpace: Protagonist third quarter 2022 results and corporate update biospace.com
Reference information only, not medical advice. Drawn from the PN-943 article, fact-checked against the cited sources. No dosing anywhere on this site.